Overview
Overview
PRECLINICAL RESEARCH COMPOUND: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ) studied exclusively in murine models for its ability to activate an aerobic-exercise gene program, enhance mitochondrial function, and improve endurance and cardiometabolic phenotypes[1][2][3]. No human trials have been conducted as of November 2025. This educational protocol reflects published murine regimens using intraperitoneal administration. Evidence Base: Preclinical only—in vivo
- Category
- Weight Loss
Mechanism
SLU-PP-332
Mechanism of action
Mechanism of action
Short version: SLU-PP-332 binds to ERRα, and to a lesser extent ERRβ and ERRγ. These are transcription factors in the cell nucleus that control how many mitochondria a cell builds, how efficiently those mitochondria burn fat, and how much oxidative capacity the cell has. When you run, muscle cells upregulate these same receptors. SLU-PP-332 does it pharmacologically. Think of ERRα as the master volume knob for a cell's aerobic machinery — SLU-PP-332 turns that knob up. ERRα is highly expressed in energy-demanding tissues such as skeletal muscle, heart, brown adipose tissue, and liver. When activated, it switches on genes for mitochondrial biogenesis, oxidative phosphorylation, the TCA cycle, and fatty acid β-oxidation. In the Billon 2023 paper, a single 25 mg/kg intraperitoneal dose in mice was enough to induce an acute aerobic exercise transcriptional signature in muscle within hours. Cell assays show SLU-PP-332 activates all three ERR isoforms but is roughly four-fold more potent at ERRα than ERRγ , with ERRβ in between (ERRα EC50 ≈ 98 nM, ERRγ EC50 ≈ 430 nM). ERRα works in partnership with PGC-1α, the master coactivator of mitochondrial biogenesis. Together they drive expression of nuclear-encoded mitochondrial genes, increasing both the number and efficiency of mitochondria in muscle and cardiac tissue. In the Billon 2023 study, 50 mg/kg twice daily for 28 days increased succinate dehydrogenase-positive oxidative muscle fibers and raised OXPHOS complex protein levels. In diet-induced obese mice and ob/ob mice, 50 mg/kg twice daily for 28 days increased whole-body energy expenditure and fatty acid oxidation, reduced fat mass, lowered cholesterol and triglycerides, and improved insulin sensitivity without changing food intake . That is a metabolic-rate mechanism, not an appetite-suppression mechanism like Semaglutide or Tirzepatide . In a pressure-overload heart-failure mouse model, six weeks of SLU-PP-332 improved ejection fraction, reduced fibrosis, and increased survival. The authors attributed the effect mainly to ERRγ engagement in cardiomyocytes, which normalized fatty acid metabolism and mitochondrial function without reversing hypertrophy itself. The practical takeaway is that ERRα appears to drive most skeletal-muscle effects, while ERRγ carries more of the cardiac signal. Put together, SLU-PP-332 reproduces many of the cellular adaptations of endurance training at the transcriptional level. What it does not reproduce is the mechanical loading of actual exercise, so tendon, bone, and connective-tissue adaptations are not part of the promise. It is a metabolic research tool, not a substitute for training.
Key research findings
- 01
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ) with the highest reported potency at ERRα. In a skeletal-muscle cell line it increased mitochondrial function and cellular respiration and triggered an ERRα-dependent gene program overlapping with the acute aerobic-exercise response, which is why it is described in the literature as an 'exercise mimetic' / ERR chemical probe (in vitro / cell-based; ACS Chem Biol 2023, PMID 36988910, doi:10.1021/acschembio.2c00720).
- 02
In mice, SLU-PP-332 increased type IIa oxidative skeletal-muscle fibers and enhanced running endurance, with ERRα activation reported as critical for the endurance effect (animal model; ACS Chem Biol 2023, PMID 36988910).
- 03
In diet-induced obese and ob/ob mice, SLU-PP-332 administration was associated with increased energy expenditure and fatty-acid oxidation, decreased fat-mass accumulation, and improved insulin sensitivity; the researchers attributed the reduction in fat mass to increased energy expenditure rather than to appetite/food-intake suppression (animal model; J Pharmacol Exp Ther 2023, PMID 37739806, doi:10.1124/jpet.123.001733).
- 04
Two structurally distinct pan-ERR agonists (SLU-PP-332 and the related SLU-PP-915) improved ejection fraction, reduced fibrosis, and increased survival in a mouse pressure-overload heart-failure model, with multi-omics work identifying ERRγ as the main mediator of the metabolic/transcriptional response (animal model + in vitro; Circulation 2023, PMID 37961903, doi:10.1161/CIRCULATIONAHA.123.066542).
- 05
In a pilot study, primary myoblasts isolated from skeletal muscle of physically inactive women and treated with SLU-PP-332 showed upregulation of PGC-1α, ERRα, SIRT1, and FNDC5, reduced markers of oxidative stress/senescence, and increased myotube formation. This is human-derived cell culture work, not in vivo human dosing (ex vivo / human primary cells; Front Physiol 2025, PMID 40692696, doi:10.3389/fphys.2025.1616693).
- 06
A 2026 systematic review of 2020–2024 preclinical literature concluded pan-ERR agonism (SLU-PP-332 / SLU-PP-915) is a promising exercise-mimetic strategy in animal and cell models but explicitly stated that clinical trials are still needed to confirm efficacy and safety in humans. Separately, SLU-PP-332 has been reported to lack oral bioavailability (dosed by injection in rodent studies), which motivated the orally bioavailable analogue SLU-PP-915 (systematic review + animal model; Rev Med Chil 2026, PMID 42024694, doi:10.4067/s0034-98872026000200237; J Pharmacol Exp Ther 2025, PMID 41421047).
Primary source: Billon 2023 (ACS Chemical Biology): Preclinical in vivo, 15-28 days, C57BL/6J mice (n = 8-10 per group). 25 mg/kg IP for 15 days increased treadmill endurance; 50 mg/kg twice daily for 28 days raised oxidative muscle fibers and OXPHOS proteins. Billon 2024 (Journal of Pharmacology and Experimental Therapeutics): Preclinical in vivo, 12-28 days, DIO C57BL/6J and ob/ob mice (n = 7-8 per group). 50 mg/kg twice daily reduced fat mass, lowered cholesterol and triglycerides, reduced adipocyte size, and improved glucose tolerance. Xu 2024 (Circulation): Preclinical in vivo, 6 weeks, C57BL/6J mice, pressure-overload TAC heart-failure model. Improved ejection fraction, reduced fibrosis, and increased survival; effects mediated mainly via ERRγ in cardiomyocytes. Wang 2023 (American Journal of Pathology): Preclinical in vivo, 8 weeks, aged mice, aging-kidney model. 25 mg/kg/day reduced albuminuria, preserved podocin, reversed mitochondrial dysfunction and inflammation. Human-trial gap: No registered or completed human clinical trial as of June 2026 per ClinicalTrials.gov. All efficacy claims circulating for SLU-PP-332 in humans rely on mouse-to-human extrapolation.
Protocol Reference
Protocol reference
Commonly cited research range: 1.25–2.5 mg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Daily — community subcutaneous range
250 mcg to 1.5 mg per day
| Phase | Reference amount | Units / volume |
|---|---|---|
| Daily — community subcutaneous range | 250 mcg to 1.5 mg per day | 15–90 units (0.15–0.90 mL) |
Titration protocol
- Ongoing — once dailyStart250 mcg to 1.5 mg per day
Drawn from a reconstituted 5 mg vial at 2,500 mcg/mL; 250 mcg = 10 units, 500 mcg = 20 units, 1 mg = 40 units, 1.5 mg = 60 units on a U-100 syringe. Source reference cycle lengths: 4 weeks (review at Week 4), 6-8 weeks (review at Week 6), or 12 weeks (review at Week 8 and Week 12).
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️01 Warm the vial — Let the lyophilized vial reach room temperature for 5-10 minutes.
- 02🧴02 Wipe the stoppers — Use an alcohol swab on both the SLU-PP-332 vial and the bacteriostatic water vial.
- 03💉Draw 3 mL bacteriostatic water into a sterile syringe — this 5 mg vial yields 1.67 mg/mL.
- 04💧04 Inject slowly — Inject the water down the inside wall of the vial — do not blast diluent directly onto the powder.
- 05🔄05 Swirl to dissolve — Swirl gently until fully dissolved. Do not shake vigorously.
- 06🏷️06 Label the vial — Note the reconstitution date and the final concentration (2,500 mcg/mL) on the vial label.
- 07❄️07 Refrigerate and protect from light — Store at 2-8°C (35.6-46.4°F) protected from light.
- 08💉Critical: This guide reflects preclinical murine research only. This information is for educational and research purposes exclusively—not for human consumption. No human safety or efficacy data exist for SLU-PP-332.
Additional storage notes
-4°F (-20°C) long-term, or 35.6-46.4°F (2-8°C)
35.6-46.4°F (2-8°C), protect from light
Cool, dry room temperature, away from light and humidity
-112°F (-80°C) ideal; -4°F (-20°C) acceptable
Clinical Evidence
Clinical evidence
Studied exclusively in murine models as an exercise-mimetic research compound; no human data exist.
Billon 2023 (ACS Chemical Biology): Preclinical in vivo, 15-28 days, C57BL/6J mice (n = 8-10 per group). 25 mg/kg IP for 15 days increased treadmill endurance; 50 mg/kg twice daily for 28 days raised oxidative muscle fibers and OXPHOS proteins. Billon 2024 (Journal of Pharmacology and Experimental Therapeutics): Preclinical in vivo, 12-28 days, DIO C57BL/6J and ob/ob mice (n = 7-8 per group). 50 mg/kg twice daily reduced fat mass, lowered cholesterol and triglycerides, reduced adipocyte size, and improved glucose tolerance. Xu 2024 (Circulation): Preclinical in vivo, 6 weeks, C57BL/6J mice, pressure-overload TAC heart-failure model. Improved ejection fraction, reduced fibrosis, and increased survival; effects mediated mainly via ERRγ in cardiomyocytes. Wang 2023 (American Journal of Pathology): Preclinical in vivo, 8 weeks, aged mice, aging-kidney model. 25 mg/kg/day reduced albuminuria, preserved podocin, reversed mitochondrial dysfunction and inflammation. Human-trial gap: No registered or completed human clinical trial as of June 2026 per ClinicalTrials.gov. All efficacy claims circulating for SLU-PP-332 in humans rely on mouse-to-human extrapolation.
- 01SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ) with the highest reported potency at ERRα. In a skeletal-muscle cell line it increased mitochondrial function and cellular respiration and triggered an ERRα-dependent gene program overlapping with the acute aerobic-exercise response, which is why it is described in the literature as an 'exercise mimetic' / ERR chemical probe (in vitro / cell-based; ACS Chem Biol 2023, PMID 36988910, doi:10.1021/acschembio.2c00720).
- 02In mice, SLU-PP-332 increased type IIa oxidative skeletal-muscle fibers and enhanced running endurance, with ERRα activation reported as critical for the endurance effect (animal model; ACS Chem Biol 2023, PMID 36988910).
- 03In diet-induced obese and ob/ob mice, SLU-PP-332 administration was associated with increased energy expenditure and fatty-acid oxidation, decreased fat-mass accumulation, and improved insulin sensitivity; the researchers attributed the reduction in fat mass to increased energy expenditure rather than to appetite/food-intake suppression (animal model; J Pharmacol Exp Ther 2023, PMID 37739806, doi:10.1124/jpet.123.001733).
- 04Two structurally distinct pan-ERR agonists (SLU-PP-332 and the related SLU-PP-915) improved ejection fraction, reduced fibrosis, and increased survival in a mouse pressure-overload heart-failure model, with multi-omics work identifying ERRγ as the main mediator of the metabolic/transcriptional response (animal model + in vitro; Circulation 2023, PMID 37961903, doi:10.1161/CIRCULATIONAHA.123.066542).
- 05In a pilot study, primary myoblasts isolated from skeletal muscle of physically inactive women and treated with SLU-PP-332 showed upregulation of PGC-1α, ERRα, SIRT1, and FNDC5, reduced markers of oxidative stress/senescence, and increased myotube formation. This is human-derived cell culture work, not in vivo human dosing (ex vivo / human primary cells; Front Physiol 2025, PMID 40692696, doi:10.3389/fphys.2025.1616693).
- 06A 2026 systematic review of 2020–2024 preclinical literature concluded pan-ERR agonism (SLU-PP-332 / SLU-PP-915) is a promising exercise-mimetic strategy in animal and cell models but explicitly stated that clinical trials are still needed to confirm efficacy and safety in humans. Separately, SLU-PP-332 has been reported to lack oral bioavailability (dosed by injection in rodent studies), which motivated the orally bioavailable analogue SLU-PP-915 (systematic review + animal model; Rev Med Chil 2026, PMID 42024694, doi:10.4067/s0034-98872026000200237; J Pharmacol Exp Ther 2025, PMID 41421047).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to SLU-PP-332.
- 01Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology (2023)et al. (2023)
- 02Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler A, Elgendy B, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics (2024)et al. (2024)
- 03Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation (2024)et al. (2024)
- 04Wang XX, Myakala K, Libby AB, Krawczyk E, Panov J, Jones BA, et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology (2023)et al. (2023)
- 05MedChemExpress SLU-PP-332 | ERR Agonist product data sheet. MedChemExpress (2024)et al. (2024)
- 06Cayman Chemical SLU-PP-332 product data sheet (CAS 303760-60-3). Cayman Chemical (2024)et al. (2024)
- 07Shahien M, Elgendy B, Hegazy L, Patouret R, Walker JK, Burris TP. Development of synthetic agonists of estrogen-related receptors (ERRs) based on an aniline-based pan-agonist scaffold. Journal of Medicinal Chemistry (precursor scaffold context) (2023)et al. (2023)
- 08Frontiers in Physiology editorial team Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Frontiers in Physiology (2025)et al. (2025)
- 09Nasri H. New hopes on 'SLU-PP-332' as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view. Journal of Renal Endocrinology (2024)et al. (2024)
- 10PubChem PubChem entry for SLU-PP-332 (CAS 303760-60-3). PubChem / NCBI (2024)et al. (2024)
- 11ClinicalTrials.gov Registry search for 'SLU-PP-332' confirming no registered or completed human trials. ClinicalTrials.gov (2026)et al. (2026)
- 12World Anti-Doping Agency WADA Prohibited List — class S4.5 metabolic modulators (ERR agonists as a class). WADA (2026)et al. (2026)
Observed Effects
Observed effects in cited research
Mouse-study observations
- In the Billon 2023 and Billon 2024 studies, mice dosed at 25-50 mg/kg IP for up to 28 days showed no overt toxicity, no sickness-related weight loss, no liver-enzyme signal at the doses tested, and no cardiac dysfunction. In the Xu 2024 heart-failure study the compound improved cardiac function rather than worsening it; in the Wang 2023 kidney study it was renoprotective rather than nephrotoxic.
Broad tissue exposure
- ERR receptors are widely expressed across heart, brain, kidney, liver, adipose tissue, and gut, so systemic pan-ERR agonism is not tissue-selective.
Appetite changes
- Some community users report appetite changes, though food intake was not significantly altered in the DIO mouse studies.
Sleep disturbance and stimulation
- Informal reports describe a more stimulatory feeling and sleep disruption; no controlled data exist.
Resting heart rate
- A subset of community users report increased resting heart rate. There is no controlled human data confirming or quantifying this effect.
Cardiovascular unknowns
- Chronic high-dose human data do not exist, even though preclinical agonist data looks cardioprotective in heart-failure models.
Oncology unknowns
- ERRα participates in some cancer-metabolism pathways, leaving long-term cancer-risk questions open.
Drug interactions
- Hepatic metabolism and CYP-pathway interactions in humans are uncharacterized.
Serious adverse events
- No serious adverse events have been reported in any published rodent study of SLU-PP-332 at the doses and durations tested. No long-term toxicology study beyond 12 weeks has been published in any species. Washout in mice appears relatively fast given the short exposure window, but that is an animal-PK inference, not a human fact.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Evidence is strictly preclinical (cell and/or animal models); it is a research compound, not a therapy, and has not been evaluated for human safety. Consult a licensed healthcare professional for any clinical decisions.
- Pregnant or breastfeeding individuals; people under 18; people with active or recent cancer (ERRα participates in some cancer-metabolism pathways); people with known cardiovascular disease, arrhythmia, or uncontrolled hypertension (chronic high-dose human data do not exist); people with significant liver or kidney impairment; people on stimulants, hormone modulators, or experimental metabolic compounds without clinician oversight; competitive athletes subject to WADA testing (ERR agonists fall under WADA class S4.5 metabolic modulators as a class, even though SLU-PP-332 is not separately named).
- Because SLU-PP-332 has no human safety profile, any research planning that involves human exposure should be done under qualified clinician oversight. PDP does not provide medical advice, and nothing on this page substitutes for individualized clinical evaluation.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| SLU-PP-332this | A synthetic pan-agonist of estrogen-related receptors (ERR alpha/beta/gamma) studied for activation of an aerobic-exercise-like gene program and increased oxidative metabolism. | — | Investigational / RUO |
| Survodutide | An investigational long-acting dual agonist of GLP-1 and glucagon receptors studied for appetite regulation and increased energy expenditure. | subcutaneous | Investigational / RUO |
| Tirzepatide | Activates both GIP and GLP-1 receptors, providing synergistic effects on insulin secretion, glucose control, and appetite regulation. | subcutaneous | Investigational / RUO |
| 5-Amino-1MQ | Inhibits nicotinamide N-methyltransferase (NNMT), increasing NAD+ availability and enhancing mitochondrial metabolism. | oral, subcutaneous | Investigational / RUO |
| Adipotide | A peptidomimetic that targets prohibitin on the vasculature of white adipose tissue and delivers a pro-apoptotic sequence, studied for selective reduction of fat-tissue blood supply. | subcutaneous | Investigational / RUO |
| SNAP-8 | A synthetic acetylated octapeptide (an extended Argireline analog) studied for topical reduction of muscle contraction by interfering with SNARE-complex formation at the neuromuscular junction. | subcutaneous | Investigational / RUO |
| SS-31 | A mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron-transport-chain organization and reducing reactive oxygen species. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
SLU-PP-332 is a synthetic small-molecule pan-ERR agonist developed in the Thomas Burris lab. It activates the same nuclear receptors that endurance exercise activates, which is why it is often described as an exercise mimetic. Published mouse studies report increased treadmill endurance, fat-mass reduction in obese mice, improved cardiac function in heart-failure models, and reduced inflammation in aging-kidney models. Despite the 'peptide' label used in many product listings, SLU-PP-332 is not a peptide — it is a small organic molecule.
There is no human-validated starting dose. Published murine studies used 25-50 mg/kg intraperitoneal injection once or twice daily. Two community patterns circulate for humans: a low-dose oral pattern (250 mcg to ~1.5 mg once daily) using small-strength vendor capsules, and a higher pattern anchored to the supplier's 50 mg tablet (1 tablet daily). A separate high-dose extrapolation lands near 650 mg/day based on mouse-to-human allometric scaling, but no human has been studied at any dose. None of these are dosing recommendations.
The current featured supplier carries SLU-PP-332 as a 50 mg oral tablet in a 60-tablet bottle. Community oral protocols range from a 25 mg split-tablet pattern to a 50 mg or 100 mg daily pattern. Oral bioavailability in humans has not been formally published, so any tablet dose is a community pattern, not a clinically validated dose. See the PepPal supplier rankings for broader sourcing context.
Tablets are easier to handle, need no reconstitution, and dose by bottle and tablet count. Injectable vials are the format used in every published animal study, but those used intraperitoneal injection in mice — not subcutaneous injection in humans. Community injectable users reconstitute a 5 mg or 10 mg vial with bacteriostatic water and inject subcutaneously. Oral bioavailability and pharmacokinetics for SC human administration are not published, so there is no clinical answer to which format is more effective.
A formal human pharmacokinetic half-life has not been published. In the Billon 2023 paper, mice given 30 mg/kg IP still showed measurable plasma and muscle concentrations at 6 hours post-injection, which helps explain why twice-daily dosing was used in efficacy studies.
For a 5 mg vial, adding 2 mL of bacteriostatic water gives a 2,500 mcg/mL concentration where a 500 mcg dose equals 20 units on a U-100 insulin syringe. Other vial sizes and concentrations are tabulated in the reconstitution section above. For exact draw volumes, use the Pep Pal reconstitution calculator .
No. SLU-PP-332 is not approved by the FDA for any indication. It is sold by research suppliers as a research-use compound. There is no registered or completed human clinical trial program on ClinicalTrials.gov as of June 2026.
There is no human observed effect dataset. Published mouse studies did not report overt toxicity, liver-enzyme issues, or sickness-related weight loss at 25-50 mg/kg IP for up to 8 weeks. Community reports describe mild appetite changes, sleep disturbance, and increased resting heart rate in some users, but these are uncontrolled observations.
A faint pale-yellow tint can occur with small-molecule compounds in aqueous solution, but a deepening yellow shade often indicates oxidation or degradation from light or temperature excursions. If the color shifts noticeably from the initial appearance, treat the vial as potentially degraded and contact the supplier rather than continuing use. Formal stability data for community reconstitution conditions has not been published.
SLU-PP-332 works at the nuclear-receptor level through ERRα / β / γ. MOTS-c is a mitochondrial-derived peptide with AMPK-linked signaling, and AOD-9604 is a GH-fragment-derived lipolysis compound. SLU-PP-332 has the strongest preclinical exercise-mimetic signature of the three, but zero human clinical data.
No human study has evaluated SLU-PP-332 in combination with any other compound. Theoretical pairings appear in community discussion, but none are clinically validated, and combining experimental compounds compounds the unknowns. PDP does not provide stacking recommendations involving SLU-PP-332. For broader stacking context, see the PepPal peptide stacking guide .
In published mouse studies, 50 mg/kg IP twice daily for 28 days is the highest-dose, longest-duration regimen reported in peer-reviewed literature. Human-equivalent-dose extrapolation from that protocol lands around 650 mg/day for an 80 kg adult, but no human has been studied at any dose in a published trial. This is not a dosing recommendation.
No. Everything on this page is educational research context. SLU-PP-332 is a preclinical research compound with no FDA-approved indication and no human trial program. Nothing on this page is intended as a personal dosing recommendation or as treatment guidance. Work with a qualified clinician for individual decisions.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.